Lyell Immunopharma Inc (LYEL) — Capital Reinvestment Ratio
Lyell Immunopharma Inc (LYEL) has a Capital Reinvestment Ratio of 0.41x as of December 2019, meaning it reinvests 0% of its operating cash flow ($39.47 Million) in capital expenditures ($16.05 Million). Check Lyell Immunopharma Inc (LYEL) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Lyell Immunopharma Inc Capital Reinvestment Ratio (2019–2019)
This chart tracks Lyell Immunopharma Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Lyell Immunopharma Inc.
Annual Capital Reinvestment Ratio for Lyell Immunopharma Inc (2019–2019)
Year-by-year Capital Reinvestment Ratio for Lyell Immunopharma Inc from 2019 to 2019. See Lyell Immunopharma Inc (LYEL) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.41x | $39.47 Million | $16.05 Million | — |